Recent updates to the Universal Influenza Vaccine Technology Landscape

Reactogenicity, safety, and immunogenicity of Osivax’s NP-based OVX836 vaccine candidate co-administered with a licensed seasonal influenza vaccine in a Phase 2a trial NCT05284799, published in Groth 2025
Preclinical evaluation of intranasal delivery of a multi-subtype consensus NA-M2e VLP vaccine candidate, reported in Raha 2025
Development of recombinant H3 COBRA HA antigens using A(H3N2) HA sequences circulating from 2018-2022 to elicit broadly protective antibodies against A(H3N2) strains in animal models, reported in Allen 2025
Results of a Phase 3 trial NCT06097273 of Moderna’s mRNA-1083 combination COVID+influenza vaccine candidate, published in Rudman Spergel 2025
Preclinical evaluation of a centralized consensus NA immunogen delivered via an adenovirus vector, reported in Pekarek 2025
Results of a Phase 1/2 trial NCT05052697 of Pfizer’s next-generation quadrivalent mRNA vaccine candidate, qIRV, reported in Branche 2025

For more recent updates and additional information, see the Landscape.